Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1996 2
1997 1
1998 2
1999 1
2003 4
2004 3
2005 1
2006 5
2007 3
2008 5
2009 3
2010 3
2011 10
2012 7
2013 6
2014 6
2015 6
2016 8
2017 12
2018 9
2019 12
2020 7
2021 7
2022 4
2023 6
2024 4
2025 9
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. Hirschfield GM, et al. Among authors: buggisch p. N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21. N Engl J Med. 2024. PMID: 38381664 Clinical Trial.
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.
Levy C, Trivedi PJ, Kowdley KV, Gordon SC, Bowlus CL, Londoño MC, Hirschfield GM, Gulamhusein A, Lawitz EJ, Vierling JM, Mayo MJ, Jacobson IM, Kremer AE, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter CA, Crittenden DB; ASSURE Investigators. Levy C, et al. Among authors: buggisch p. Am J Gastroenterol. 2025 Jun 24;121(5):1140-53. doi: 10.14309/ajg.0000000000003603. Online ahead of print. Am J Gastroenterol. 2025. PMID: 40553148 Free PMC article.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: buggisch p. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
[Strategietreffen: Virushepatitis in Deutschland eliminieren].
Tergast TL, Protzer U, Zeuzem S, Heitmann L, Sarrazin C, Lehmann M, Ingiliz P, Cornberg M, Zimmermann R, Gerlich MG, Buggisch P, Wiebner B, Wedemeyer H. Tergast TL, et al. Among authors: buggisch p. Z Gastroenterol. 2023 Feb;61(2):198-201. doi: 10.1055/a-1978-9021. Epub 2023 Feb 3. Z Gastroenterol. 2023. PMID: 36736343 Free PMC article. German. No abstract available.
[S3 guideline hepatitis C addendum].
Sarrazin C, Berg T, Buggisch P, Dollinger MM, Hinrichsen H, Hofer H, Hüppe D, Manns MP, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S. Sarrazin C, et al. Among authors: buggisch p. Z Gastroenterol. 2015 Apr;53(4):320-34. doi: 10.1055/s-0034-1399322. Epub 2015 Apr 13. Z Gastroenterol. 2015. PMID: 25867048 German. No abstract available.
Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C.
Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Hüppe D, Manns M, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S. Sarrazin C, et al. Among authors: buggisch p. Z Gastroenterol. 2014 Oct;52(10):1185-97. Z Gastroenterol. 2014. PMID: 25513400 German. No abstract available.
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.
Herta T, Dietz-Fricke C, Demir M, Sprinzl K, Pfeiffer KH, Grottenthaler JM, Buggisch P, Kremer WM, Reiter FP, Geier A, Schramm C, Merle U, Neumann-Haefelin C, Tacke F, Berg T, Wedemeyer H, Deterding K, Wiegand J. Herta T, et al. Among authors: buggisch p. Liver Int. 2025 Nov;45(11):e70404. doi: 10.1111/liv.70404. Liver Int. 2025. PMID: 41108575 Free PMC article.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. Among authors: buggisch p. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
136 results